1 citations
,
October 2006 in “Oncology times” This study found that finasteride does not increase the risk of high-grade prostate cancer but instead improves the prostate-specific antigen test's sensitivity to detect such cancers.
January 2023 in “International Journal of Clinical and Medical Education Research” This paper discusses prostate cancer diagnosis and treatment controversies and advocates for individualized approaches, reporting no new findings.
October 2008 in “The Journal of Urology” This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.
6 citations
,
May 2008 in “Current Opinion in Oncology” This review covers recent advances in prostate cancer risk assessment, diagnosis, and treatment but does not report new clinical results; further studies on androgen deprivation therapy's cardiovascular risks are particularly noted.
March 2026 in “European Urology Focus” This study found that the 4Kscore model, when adjusted for kallikrein marker changes due to finasteride use, improved the prediction of high-grade prostate cancer compared to adjusted total PSA alone in men taking 5-α-reductase inhibitors.